Eli Lilly and Company
LLY
$989.87
$22.882.37%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 55.54% | 42.55% | 53.87% | 37.64% | 45.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 55.54% | 42.55% | 53.87% | 37.64% | 45.18% |
| Cost of Revenue | 60.76% | 40.28% | 38.58% | 12.79% | 32.95% |
| Gross Profit | 54.44% | 43.04% | 57.45% | 43.55% | 48.06% |
| SG&A Expenses | 18.88% | 24.79% | 32.37% | 32.19% | 34.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 34.93% | 29.69% | 32.10% | 22.47% | 23.12% |
| Operating Income | 84.42% | 62.32% | 86.82% | 61.28% | 93.81% |
| Income Before Tax | 156.08% | 64.07% | 355.33% | 92.66% | 36.27% |
| Income Tax Expenses | 108.61% | 159.11% | 166.93% | 102.82% | 137.72% |
| Earnings from Continuing Operations | 168.07% | 50.52% | 475.34% | 90.78% | 23.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 168.07% | 50.52% | 475.34% | 90.78% | 23.01% |
| EBIT | 84.42% | 62.32% | 86.82% | 61.28% | 93.81% |
| EBITDA | 78.44% | 58.85% | 78.81% | 57.35% | 83.82% |
| EPS Basic | 169.33% | 51.39% | 477.97% | 91.42% | 23.30% |
| Normalized Basic EPS | 92.74% | 61.39% | 88.04% | 60.37% | 92.92% |
| EPS Diluted | 169.93% | 51.39% | 480.37% | 91.77% | 23.39% |
| Normalized Diluted EPS | 92.85% | 61.39% | 88.48% | 60.62% | 93.15% |
| Average Basic Shares Outstanding | -0.47% | -0.57% | -0.46% | -0.33% | -0.23% |
| Average Diluted Shares Outstanding | -0.52% | -0.57% | -0.69% | -0.49% | -0.35% |
| Dividend Per Share | 15.33% | 15.38% | 15.38% | 15.38% | 15.38% |
| Payout Ratio | -0.57% | -0.23% | -0.80% | -0.40% | -0.06% |